TWi Biotechnology, Inc. Announced the initiation of Phase 2 Proof-of-Concept Clinical Trial of AC-203 for Treatment of Inherited Epidermolysis Bullosa

TAIPEI, Taiwan, Oct. 20, 2018 /PRNewswire/ -- TWi Biotechnology, Inc. (6610 TTO), a clinical stage biotechnology company focused on developing novel inhibitors of inflammasomes, today announced that i...